Real-world data show that Enhertu benefits those with HR+ breast cancer, whereas Trodelvy is effective as an initial treatment for HER2-null/HER2– disease.

Q2 2025 Earnings Call Transcript August 13, 2025 Mersana Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Good afternoon, everyone. Thank you for standing by. Welcome to the ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Gilead Sciences ( NASDAQ: GILD) was upgraded to Buy from Hold at Truist after the company raised full year sales and profit ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

(Nasdaq: GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first ...

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and ...

A phase 1/2 trial reveals sacituzumab tirumotecan shows manageable toxicity and promising antitumor activity in patients with ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...